AGIOS PHARMACEUTICALS INC
AGIONASDAQ🏆 #1824 by market capEarnings Nov 5US Equity
$37.24▼ $0.86 (−2.26%)
Market closed · at closeTrack AGIO
Get earnings, price moves & breaking news on Telegram
24h▼ 2.3%
7d▲ 0.6%
14d▲ 18.7%
30d▲ 12.0%
ytd▲ 36.8%
1y▼ 13.7%
🏦Market Cap
$2.22B
Small Cap
📈Revenue Growth (YoY)
48.0%
High Growth
📊Gross Margin
87.9%
High
💵FCF Margin
-371.4%
Thin
⚖️P/S Ratio
22.7x
Expensive
Otter Score
72
Strong
Trading Snapshot
- Day Range
- $36.76 – $38.45
- 52-Week Range
- $22.24 – $46.00
- Volume (shares)
- 78,133
- Avg Volume (shares)
- —
- Shares Outstanding
- 59.7M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $54M
- Last Q Revenue
- $45M
- P/E Ratio
- -5.3
- P/S Ratio
- 22.7x
- EPS (TTM)
- $-6.91
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.1%
AGIOS PHARMACEUTICALS INC
AGIOFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$54M▲ +48.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
78.7%▼ −11.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$472M▲ +10.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$377M▼ −3.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
58.3M▲ +2.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$49M▲ +$30M YoY
StockOtter · stockotter.spaceAbout AGIOS PHARMACEUTICALS INC
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
72/100
Analyst data unavailable.
Latest News & Updates
News unavailable.